Filing Scope and Business Context
Important identity note: The supplied filing is for Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), not Spyre Therapeutics, Inc. The filing is a Form 10-K for the fiscal year ended December 31, 2018; it is not a standalone 2018 fourth-quarter filing, although unaudited quarterly data are included.
Aeglea is a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare genetic diseases and cancer. Its lead candidate, pegzilarginase, was being developed for Arginase 1 Deficiency and arginine-dependent cancers. The company reported 61 full-time employees and operated as a single reporting segment.
Financial Results and Key Metrics
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Grant revenue | $3.9 million | $5.2 million | Down 25% |
| Research and development expense | $36.7 million | $22.8 million | Up 61% |
| General and administrative expense | $12.6 million | $10.1 million | Up 25% |
| Total operating expenses | $49.4 million | $32.9 million | Up 50% |
| Operating loss | $45.5 million | $27.7 million | Worsened 64% |
| Net loss | $44.3 million | $27.2 million | Worsened 63% |
| Basic and diluted loss per share | $2.13 | $1.80 | Higher loss per share |
| Operating cash flow | $(32.2) million | $(24.6) million | Greater cash use |
| Cash, cash equivalents and marketable securities | $74.5 million | $50.3 million | Up 48% |
| Working capital | $66.4 million | $49.4 million | Up 35% |
| Total liabilities | $10.3 million | $5.7 million | Up 80% |
The company had no product revenue and relied on grant revenue, equity financing and investment income. Grant revenue represented the company’s only reported revenue and the CPRIT grant ended in May 2018 after the full $19.8 million award had been collected and recognized over its term.
Approximate margins were highly negative: operating margin was approximately negative 1,169% and net margin approximately negative 1,141%, based on grant revenue only. The filing states that the company had no debt or credit facility. Accumulated deficit was $116.9 million at December 31, 2018.
Material Changes Versus Prior Comparable Period
- Research and development spending increased by $13.9 million, primarily due to expanded clinical development, higher personnel costs, manufacturing activities and nonclinical work for pegzilarginase.
- Clinical expenses increased by approximately $9.5 million as the company advanced the Arginase 1 Deficiency program, solid-tumor cohorts and the pembrolizumab combination trial.
- General and administrative expense increased by $2.6 million, including $1.1 million of additional non-cash stock-based compensation.
- Grant revenue declined by $1.3 million as the CPRIT grant approached completion and ended.
- Cash used in operations increased by $7.6 million, while net loss increased by $17.1 million.
- The company raised $54.0 million net from public and at-the-market common-stock offerings during 2018, increasing issued and outstanding shares from 16.7 million to 24.1 million at year-end.
- In February 2019, after year-end, the company raised approximately $64.5 million net through a common-stock and pre-funded-warrant offering.
Guidance, Outlook, Risks and Unusual Items
- Management expected to initiate the global pivotal Phase 3 PEACE trial for Arginase 1 Deficiency in the second quarter of 2019, with topline data anticipated in the first quarter of 2021.
- Management expected topline data from the pegzilarginase/pembrolizumab Phase 2 small-cell lung cancer study in the first half of 2020.
- Management estimated that available cash, cash equivalents and marketable securities at year-end, together with February 2019 financing proceeds, would fund operations through the first quarter of 2021. This estimate depended on assumptions that could prove incorrect, and additional financing will be required for longer-term development.
- Clinical results remained early-stage and uncertain. The company disclosed hypersensitivity events and anti-drug antibodies in the Arginase 1 Deficiency program, as well as serious adverse events in oncology studies, including events considered possibly or probably treatment-related.
- The company discontinued pegzilarginase development in AML and MDS in December 2017 because of insufficient evidence of clinical benefit.
- Development depends heavily on pegzilarginase; other candidates, including AEB4104, AEB5100, AEB3103 and AEB2109, were preclinical or in IND-enabling development.
- The company relied on third-party contract research, manufacturing and clinical organizations and had no redundant supply source for bulk drug substance. A new master services agreement was entered into with Fujifilm Diosynth in November 2018.
- Potential future obligations included University of Texas milestone payments of up to $6.4 million per licensed product candidate, low-single-digit royalties and sublicense revenue sharing. The company also owed potential royalties to CPRIT on future products or licenses based on grant-funded results.
- Key risks included clinical failure, patient-enrollment delays in rare diseases, regulatory delays, manufacturing and supply constraints, immunogenicity, competition, uncertain reimbursement, intellectual-property challenges, future equity dilution and the need for additional capital.
Most Important Facts for Investors to Verify
- Confirm that the intended issuer is Aeglea BioTherapeutics rather than Spyre Therapeutics; the supplied filing does not identify Spyre.
- Review the audited financial statements and notes for cash runway, accumulated deficit, stock issuances and subsequent February 2019 financing.
- Assess whether the Phase 3 PEACE trial met its enrollment, timing, endpoint and regulatory objectives.
- Verify updated safety, immunogenicity and efficacy data for pegzilarginase in Arginase 1 Deficiency and oncology indications.
- Evaluate dilution from subsequent equity offerings, pre-funded warrants, stock options and the remaining at-the-market authorization.
- Review the status of University of Texas license obligations, CPRIT royalty provisions and third-party manufacturing arrangements.
- Confirm whether the company has achieved any product revenue or regulatory approval; the 2018 filing reports neither.